

# Tom Decroo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2971946/publications.pdf>

Version: 2024-02-01

111  
papers

2,207  
citations

236912

25  
h-index

254170

43  
g-index

115  
all docs

115  
docs citations

115  
times ranked

2934  
citing authors

#	ARTICLE	IF	CITATIONS
1	Distribution of Antiretroviral Treatment Through Self-Forming Groups of Patients in Tete Province, Mozambique. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e39-e44.	2.1	167
2	Social Consequences of Ebola Containment Measures in Liberia. <i>PLoS ONE</i> , 2015, 10, e0143036.	2.5	161
3	Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. <i>International Health</i> , 2013, 5, 169-179.	2.0	136
4	Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. <i>Tropical Medicine and International Health</i> , 2014, 19, 514-521.	2.3	98
5	Psychological Distress among Ebola Survivors Discharged from an Ebola Treatment Unit in Monrovia, Liberia – A Qualitative Study. <i>Frontiers in Public Health</i> , 2016, 4, 142.	2.7	94
6	The Contribution of Ebola Viral Load at Admission and Other Patient Characteristics to Mortality in a MÃ©decins Sans FrontiÃ©res Ebola Case Management Centre, Kailahun, Sierra Leone, June–October 2014. <i>Journal of Infectious Diseases</i> , 2015, 212, 1752-1758.	4.0	88
7	Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. <i>Eurosurveillance</i> , 2014, 19, .	7.0	76
8	Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 239-245.	1.2	65
9	A Qualitative Assessment of a Community Antiretroviral Therapy Group Model in Tete, Mozambique. <i>PLoS ONE</i> , 2014, 9, e91544.	2.5	59
10	Sustainability of a community-based antiretroviral care delivery model – a qualitative research study in Tete, Mozambique. <i>Journal of the International AIDS Society</i> , 2014, 17, 18910.	3.0	51
11	How to bring residents’ psychosocial well-being to the heart of the fight against Covid-19 in Belgian nursing homes? A qualitative study. <i>PLoS ONE</i> , 2021, 16, e0249098.	2.5	49
12	Adapting a community-based ART delivery model to the patients’ needs: a mixed methods research in Tete, Mozambique. <i>BMC Public Health</i> , 2014, 14, 364.	2.9	48
13	Effect of Community ART Groups on retention-in-care among patients on ART in Tete Province, Mozambique: a cohort study. <i>BMJ Open</i> , 2017, 7, e016800.	1.9	45
14	Lessons learned during down referral of antiretroviral treatment in Tete, Mozambique. <i>Journal of the International AIDS Society</i> , 2009, 12, 6-6.	3.0	43
15	Dangerous crossing: demographic and clinical features of rescued sea migrants seen in 2014 at an outpatient clinic at Augusta Harbor, Italy. <i>Conflict and Health</i> , 2016, 10, 14.	2.7	41
16	Community ART Support Groups in Mozambique: The Potential of Patients as Partners in Care. <i>PLoS ONE</i> , 2016, 11, e0166444.	2.5	40
17	Delivery of an Ebola Virus-Positive Stillborn Infant in a Rural Community Health Center, Sierra Leone, 2015. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 417-419.	1.4	39
18	Are Expert Patients an Untapped Resource for ART Provision in Sub-Saharan Africa?. <i>AIDS Research and Treatment</i> , 2012, 2012, 1-8.	0.7	38

#	ARTICLE	IF	CITATIONS
19	Post-Traumatic Stress Reactions in Ebola Virus Disease Survivors in Sierra Leone. <i>Emergency Medicine: Open Access</i> , 2015, 05, .	0.1	38
20	Ebola Virus in Breast Milk in an Ebola Virusâ€œPositive Mother with Twin Babies, Guinea, 2015. <i>Emerging Infectious Diseases</i> , 2016, 22, 759-760.	4.3	36
21	Patients struggle to access effective health care due to ongoing violence, distance, costs and health service performance in Afghanistan. <i>International Health</i> , 2015, 7, 169-175.	2.0	35
22	Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. <i>Lancet Microbe</i> , The, 2020, 1, e74-e83.	7.3	35
23	Lactating mothers infected with Ebola virus: EBOV RT-PCR of blood only may be insufficient. <i>Eurosurveillance</i> , 2015, 20, .	7.0	35
24	Short-Course Regimen for Multidrug-Resistant Tuberculosis: A Decade of Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 55.	2.4	34
25	Pretomanid for tuberculosis: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 31-42.	6.0	30
26	Describing readmissions to an Ebola case management centre (CMC), Sierra Leone, 2014. <i>Eurosurveillance</i> , 2014, 19, 20924.	7.0	27
27	Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs. <i>International Health</i> , 2017, 9, 206-214.	2.0	26
28	Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements. <i>Respiratory Medicine</i> , 2020, 161, 105844.	2.9	26
29	Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 329-339.	1.2	26
30	Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac029.	2.1	24
31	Local constraints to access appropriate malaria treatment in the context of parasite resistance in Cambodia: a qualitative study. <i>Malaria Journal</i> , 2017, 16, 81.	2.3	23
32	Getting HIV Treatment to the Most People. <i>Science</i> , 2012, 337, 298-300.	12.6	22
33	Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabweâ€™s national antiretroviral therapy programme between 2012 and 2015. <i>PLoS ONE</i> , 2020, 15, e0222309.	2.5	21
34	Community-Based ART Resulted in Excellent Retention and Can Leverage Community Empowerment in Rural Lesotho, A Mixed Method Study. <i>HIV/AIDS Research and Treatment: Open Journal</i> , 2015, 2, 44-50.	0.2	21
35	World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105822.	2.5	19
36	Characteristics and early clinical outcomes of key populations attending comprehensive community-based HIV care: Experiences from Nasarawa State, Nigeria. <i>PLoS ONE</i> , 2018, 13, e0209477.	2.5	17

#	ARTICLE	IF	CITATIONS
37	ARTadherence clubs in the Western Cape of South Africa: what does the sustainability framework tell us? A scoping literature review. <i>Journal of the International AIDS Society</i> , 2019, 22, e25235.	3.0	17
38	The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance. <i>PLoS ONE</i> , 2020, 15, e0233500.	2.5	16
39	Assessment of the MSF triage system, separating patients into different wards pending Ebola virus laboratory confirmation, Kailahun, Sierra Leone, July to September 2014. <i>Eurosurveillance</i> , 2015, 20, .	7.0	16
40	Viral load detection and management on first line ART in rural Rwanda. <i>BMC Infectious Diseases</i> , 2019, 19, 8.	2.9	15
41	Lessons learnt from TB screening in closed immigration centres in Italy. <i>International Health</i> , 2016, 8, 324-329.	2.0	13
42	Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis. <i>AIDS Research and Therapy</i> , 2021, 18, 16.	1.7	13
43	Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All" in Zimbabwe. <i>PLoS ONE</i> , 2020, 15, e0240865.	2.5	13
44	Favipiravir "a prophylactic treatment for Ebola contacts?. <i>Lancet, The</i> , 2015, 385, 2350.	13.7	12
45	Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen. <i>International Journal of Infectious Diseases</i> , 2020, 100, 357-365.	3.3	12
46	High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss. <i>European Respiratory Journal</i> , 2021, 57, 2002250.	6.7	12
47	What was the effect of the West African Ebola outbreak on health programme performance, and did programmes recover?. <i>Public Health Action</i> , 2017, 7, 1-2.	1.2	11
48	First-line tuberculosis treatment with double-dose rifampicin is well tolerated. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 499-505.	1.2	11
49	Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 831-835.	3.0	9
50	<i>Mycobacterium tuberculosis</i> <i>rpoB</i> mutations: emerging from the unknown. <i>European Respiratory Journal</i> , 2021, 58, 2100783.	6.7	9
51	Rational use of Xpert testing in patients with presumptive TB: clinicians should be encouraged to use the test-treat threshold. <i>BMC Infectious Diseases</i> , 2017, 17, 674.	2.9	8
52	Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0237355.	2.5	8
53	High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1578-1579.	5.6	8
54	Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi. <i>Journal of Clinical Medicine</i> , 2020, 9, 1873.	2.4	8

#	ARTICLE	IF	CITATIONS
55	Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya. <i>International Health</i> , 2021, 13, 272-280.	2.0	8
56	Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study. <i>International Health</i> , 2019, 11, 520-527.	2.0	7
57	Translating drug resistant tuberculosis treatment guidelines to reality in war-torn Kandahar, Afghanistan: A retrospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0237787.	2.5	7
58	Tuberculosis treatment: one-shot approach or cascade of regimens?. <i>Lancet Respiratory Medicine</i> , 2020, 8, e4-e5.	10.7	7
59	Community-Based ART Service Delivery for Key Populations in Sub-Saharan Africa: Scoping Review of Outcomes Along the Continuum of HIV Care. <i>AIDS and Behavior</i> , 2022, 26, 2314-2337.	2.7	7
60	Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India. <i>PLoS ONE</i> , 2022, 17, e0263759.	2.5	7
61	Operational Research during the Ebola Emergency. <i>Emerging Infectious Diseases</i> , 2017, 23, 1057-1062.	4.3	6
62	Blended SORT-IT for operational research capacity building: the model, its successes and challenges. <i>Global Health Action</i> , 2018, 11, 1469215.	1.9	6
63	Performance of algorithms for tuberculosis active case finding in underserved high-prevalence settings in Cambodia: a cross-sectional study. <i>Global Health Action</i> , 2019, 12, 1646024.	1.9	6
64	“I take my pills every day, but then it goes up, goes down. I don’t know what’s going on” Perceptions of HIV virological failure in a rural context in Mozambique. A qualitative research study. <i>PLoS ONE</i> , 2019, 14, e0218364.	2.5	6
65	Temporary disengagement and re-engagement in human immunodeficiency virus care in a rural county serving pastoralist communities in Kenya: a retrospective cohort study. <i>International Health</i> , 2020, 12, 95-100.	2.0	6
66	Injectables key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. <i>PLoS ONE</i> , 2020, 15, e0238016.	2.5	6
67	Knowledge transmission, peer support, behaviour change and satisfaction in post Natal clubs in Khayelitsha, South Africa: a qualitative study. <i>Reproductive Health</i> , 2020, 17, 107.	3.1	6
68	Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family. <i>Tuberculosis</i> , 2020, 122, 101922.	1.9	6
69	Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1443-1446.	1.4	6
70	Trends in tuberculosis notification and treatment outcomes in prisons: a country-wide assessment in El Salvador from 2009-2014. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2016, 39, 38-43.	1.1	6
71	Mortality among PCR negative admitted Ebola suspects during the 2014/15 outbreak in Conakry, Guinea: A retrospective cohort study. <i>PLoS ONE</i> , 2017, 12, e0180070.	2.5	5
72	Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018. <i>AIDS Research and Therapy</i> , 2022, 19, .	1.7	5

#	ARTICLE	IF	CITATIONS
73	Utilization of and Barriers to HIV and MCH Services among Community ART Group Members and Their Families in Tete, Mozambique. <i>AIDS Research and Treatment</i> , 2013, 2013, 1-8.	0.7	4
74	Lifelong ART for 20 million people in sub-Saharan Africa: communities will be key for success. <i>The Lancet Global Health</i> , 2014, 2, e262-e263.	6.3	4
75	Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1450-1461.	1.2	4
76	Community health worker-led ART delivery improved scheduled antiretroviral drug refill among men who have sex with men in Lagos State, Nigeria. <i>International Health</i> , 2021, 13, 196-198.	2.0	4
77	Operational research: did health systems in Sierra Leone recover after the 2014-15 Ebola outbreak?. <i>F1000Research</i> , 2019, 8, 792.	1.6	4
78	Burden and outcome of HIV infection and other morbidities in health care workers attending an Occupational Health Program at the Provincial Hospital of Tete, Mozambique. <i>Tropical Medicine and International Health</i> , 2011, 16, 1450-1456.	2.3	3
79	District-level strategies to control the HIV epidemic in Zimbabwe: a practical example of precision public health. <i>BMC Research Notes</i> , 2020, 13, 393.	1.4	3
80	Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 763-769.	1.2	3
81	Long-term retention and predictors of attrition for key populations receiving antiretroviral treatment through community-based ART in Benue State Nigeria: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0260557.	2.5	3
82	Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1733-1734.	3.0	2
83	Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab034.	0.9	2
84	Case Report: Therapeutic Threshold for Rifampicin-Resistant Tuberculosis in a Patient from Maputo, Mozambique. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1317-1320.	1.4	2
85	Bedaquiline can act as core drug in a standardized treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis. <i>European Respiratory Journal</i> , 2021, , 2102124.	6.7	2
86	How Second-Line Injectable Drugs Work. <i>Clinical Infectious Diseases</i> , 2021, 72, e1167-e1168.	5.8	2
87	Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan. <i>Tropical Medicine and International Health</i> , 2022, 27, 207-215.	2.3	2
88	Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2022, 27, 100299.	1.3	2
89	High mortality in non-Ebola virus disease cases: need to provide timely and effective care. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1021-1022.	9.1	1
90	Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study. <i>International Health</i> , 2023, 15, 258-264.	2.0	1

#	ARTICLE	IF	CITATIONS
91	Continuous surveillance of drug-resistant TB burden in Rwanda: a retrospective cross-sectional study. <i>International Health</i> , 0, , .	2.0	1
92	Management of falsepositive rifampicin resistant Xpert MTB/RIF â€œ Authors' reply. <i>Lancet Microbe</i> , The, 2020, 1, e239.	7.3	0
93	Human rights: finding the right balance for rifampicin-resistant TB treatment. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 327-328.	1.2	0
94	Should treatment of low-level rifampicin mono-resistant tuberculosis be different?. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2021, 23, 100240.	1.3	0
95	Predictors of Rifampicin-Resistant Tuberculosis Mortality among HIV-Coinfected Patients in Rwanda. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 47-53.	1.4	0
96	â€œI donâ€™t know when he will be backâ€ life-changing events challenge the community ART Group modelâ€ a qualitative research study, Tete, Mozambique. <i>BMC Public Health</i> , 2021, 21, 2004.	2.9	0
97	Implications of bedaquiline-resistant tuberculosis. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 166-167.	9.1	0
98	Tuberculosis among indigenous municipalities in Mexico: analysis of case notification and treatment outcomes between 2009 and 2013. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2016, 39, 32-37.	1.1	0
99	Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac037.	2.1	0
100	Title is missing!. , 2020, 15, e0222309.		0
101	Title is missing!. , 2020, 15, e0222309.		0
102	Title is missing!. , 2020, 15, e0222309.		0
103	Title is missing!. , 2020, 15, e0222309.		0
104	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
105	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
106	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
107	Injectablesâ€™ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. , 2020, 15, e0238016.		0
108	Title is missing!. , 2020, 15, e0233500.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 15, e0233500.		0
110	Title is missing!. , 2020, 15, e0233500.		0
111	Title is missing!.. , 2020, 15, e0233500.		0